Business Context and Reporting Period
This Form 8-K, filed on January 28, 2014, by Fluidigm Corporation (not Standard BioTools Inc.), reports the entry into a definitive merger agreement to acquire DVS Sciences, Inc. ("DVS US"). The filing also details a modification to Fluidigm's existing business financing agreement to facilitate the acquisition and a planned public offering of convertible senior notes.
Key Financial Metrics and Transaction Terms
- Total Merger Consideration: Approximately $207.5 million in aggregate value.
- Cash Component: Approximately $125.0 million payable to DVS US stockholders.
- Stock Component: Approximately $82.5 million in Fluidigm Common Stock, subject to a 10% collar based on volume-weighted average closing prices.
- Debt Financing: Fluidigm secured consent to issue convertible senior notes due 2034 in a principal amount of up to $220 million.
- Escrow Arrangement: Approximately 50% of the stock consideration will be held in escrow to secure indemnification obligations, released in tranches at 13 and 18 months post-closing.
- Historical Financials: The filing incorporates audited financial statements for DVS US for years ended December 31, 2011 and 2012, and unaudited statements for the nine months ended September 30, 2013, but does not explicitly state revenue or profit figures in the text body.
Material Changes and Agreements
The primary material change is the execution of the Merger Agreement, under which DVS US will become a wholly-owned subsidiary of Fluidigm. Additionally, Fluidigm amended its Business Financing Agreement with Bridge Bank, National Association, to permit the issuance of the convertible notes and to obtain consent for the acquisition. All outstanding stock options and unvested restricted stock of DVS US (excluding those held by non-continuing employees) will be assumed and converted into Fluidigm Common Stock.
Guidance, Risks, and Contingencies
- Closing Conditions: The merger is contingent upon DVS US stockholder approval (already obtained) and the consummation of the underwritten public offering of Fluidigm's convertible senior notes.
- Risk Factors: Management highlights risks related to the lack of experience in acquiring businesses, integration challenges, potential loss of key employees or customers, and intellectual property risks. There is also a risk that the anticipated revenue and operating expense synergies may not be realized.
- Forward-Looking Statements: The filing contains projections regarding the single-cell genomics market and future growth, which are subject to substantial uncertainties.
Investor Verification Checklist
- Verify the final terms of the convertible senior notes offering, including interest rates and conversion features, as the offering is a closing condition.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific indemnification caps and representations.
- Examine the unaudited pro forma financial information (Exhibit 99.4) to understand the combined entity's projected financial position.
- Confirm the status of the DVS US stockholder vote and any regulatory approvals required for the merger.
- Assess the impact of the 50% stock escrow on the immediate liquidity and ownership structure of the combined company.